GLP-1 Drug Impact on Employee Health Plans

แชร์
ฝัง
  • เผยแพร่เมื่อ 25 ธ.ค. 2024

ความคิดเห็น • 42

  • @lmt1701
    @lmt1701 2 หลายเดือนก่อน +3

    The only reason the extreme expense problem exists is because our pharmaceutical pricing system is deeply corrupt. The prices Americans pay are nothing short of criminal. No other countries have this problem. You also did not price out the savings of vastly improved long term health in no heart disease, stroke or dementia.

    • @ahealthcarez
      @ahealthcarez  2 หลายเดือนก่อน

      Thank you for sharing your thoughts.

  • @4242brvrdbd
    @4242brvrdbd 3 หลายเดือนก่อน +5

    You are explaining some of the most overwhelming and confusing topics.. and it’s making sense!

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for watching and for your feedback.

  • @billeberhart6606
    @billeberhart6606 3 หลายเดือนก่อน +2

    I love how you make the topic of healthcare so exciting and energized & how informed I feel after watching your videos.
    We have two small businesses and health insurance is just too expensive for us to buy to even offer to our staff.

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for watching!!

  • @drartithangudu
    @drartithangudu 3 หลายเดือนก่อน +7

    As an endocrinologist who directly contracts with many employers for diabetes and endocrinology care, I face the GLP1RA dilemma daily. The meds are simply too expensive. Ozempic is less than $100/month in many other countries outside the US. These meds are highly effective and transform the lives and health of many of our people living with diabetes. They are also abused. None of our employers cover for weight loss alone. One thing that we also need to consider is the cost of diabetic complications (can be hundreds of thousands to millions of dollars) and how these meds are effective at prevention. There are outcomes beyond glycemic control and weight loss like cardiovascular and renal risk reduction. This is a complex conundrum that would be fairly easily solved if the price on the drugs was not so criminally bloated.

    • @SpecialK711
      @SpecialK711 3 หลายเดือนก่อน +1

      @@drartithangudu 100% agree

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for sharing your experience.

    • @DrDarkStar68
      @DrDarkStar68 3 หลายเดือนก่อน

      Why is the obligation of private payers and Medicare (taxpayers) to subsidize the metabolic syndrome pandemic, resultant from behavioral decisions of our patients?

    • @SpecialK711
      @SpecialK711 3 หลายเดือนก่อน +1

      Many would assert that the genetically modified food sources and faulty food pyramid endorsed by FDA in 80's is what fueled the hormone disruptor - obesity issue now being uniquely seen in U.S. more than any other nation.

  • @brendagreen8607
    @brendagreen8607 3 หลายเดือนก่อน +4

    Excellent breakdown. The employers are the only ones with enough power to drive change - but it will take critical mass to go against the behemoth payers.

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for watching and sharing your thoughts.

  • @Sokrabiades
    @Sokrabiades 3 หลายเดือนก่อน +1

    This is not my field at all, but i always like to stop by this channel to learn a bit more about these topics.

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for watching.

  • @drartithangudu
    @drartithangudu หลายเดือนก่อน +1

    I think a couple of things to consider - the cessation of therapy data I have seen didn’t study reasons for cessation and was published by a PBM. In my experience (I have experience with thousands of patients with diabetes) most people stop due to cost or loss of coverage. Also this video didn’t discuss the cost of diabetic complications- hundreds of thousands to millions of dollars for a single hospitalization. I agree these meds are too expensive; but the longterm cost of diabetic complications needs to be part of the equation.

    • @ahealthcarez
      @ahealthcarez  หลายเดือนก่อน

      Thank you for sharing your thoughts.

  • @suemilkbone4868
    @suemilkbone4868 3 หลายเดือนก่อน +2

    Dr. Bricker, I think you are right that it is going to take the employers of the US to finally push single payer in America. They are the ones with the influence and power to make such a change happen. Eventually, something has got to give.

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน +1

      Thank you for sharing your thoughts.

  • @cxvzf
    @cxvzf 3 หลายเดือนก่อน +1

    Thanks for posting! I’m not sure if anyone else notices but there’s a high pitch sound in this video and it’s hard to concentrate with the squeak.

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for your feedback.

    • @vs0063
      @vs0063 2 หลายเดือนก่อน

      Nope, it's not in the video, that's on their end.

    • @cxvzf
      @cxvzf 2 หลายเดือนก่อน

      @@vs0063 thanks for debunking me. Not really a matter of opinion here. Are you younger than 40? It’s high pitch.

    • @vs0063
      @vs0063 2 หลายเดือนก่อน

      @@cxvzfI'm 53 years old, but thanks for making me feel 40. 🎉😊

    • @vs0063
      @vs0063 2 หลายเดือนก่อน

      ​​@@cxvzfI'm 53 years old, no young ears here.

  • @regularguy428
    @regularguy428 3 หลายเดือนก่อน

    Hi Dr. Bricker,
    I am big fan and love your videos. Thank you for everything you do. Would you happen to know how to get in touch with a healthcare coach that can help me with these concepts?

  • @Trun1782
    @Trun1782 3 หลายเดือนก่อน +1

    Thank you

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      Thank you for watching.

  • @SpecialK711
    @SpecialK711 3 หลายเดือนก่อน +2

    Once the patents on these meds expire, ETA 2025+ the $price will come way down, & become much more competitive & attainable.

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน +1

      Thank you for sharing your perspective.

    • @robert1200
      @robert1200 3 หลายเดือนก่อน +1

      The patents on Tirzepatide and Semaglutide still have until the 2030s

    • @drartithangudu
      @drartithangudu 3 หลายเดือนก่อน +1

      Yes parents still have a while on the weeklies. Liraglutide’s parent is up but we haven’t seen a generic yet.

    • @SpecialK711
      @SpecialK711 3 หลายเดือนก่อน

      @@robert1200 Unless you can get it from China where they expire in '26

    • @SpecialK711
      @SpecialK711 3 หลายเดือนก่อน

      @robert1200 unless you can get it from China starting in 2026

  • @mjbluth
    @mjbluth 3 หลายเดือนก่อน +1

    Why the reupload?

    • @ahealthcarez
      @ahealthcarez  3 หลายเดือนก่อน

      I made a mistake in the first version that I needed to correct. Thank you for watching.

  • @NANA-nd1kq
    @NANA-nd1kq 3 หลายเดือนก่อน

    or, offer employees $5000 (half the cost of GLP-1) if achieving proven weight loss above defined threshold in a year?
    'Tragedy of Commons' very applicable. Rationing strategy already in place, but workarounds are destroying the grass. (Posting signs: "No Grazing under certain conditions" are being ignored).
    Political regime owns the commons. Regime will not, evidently, allow perfectly reasonable solutions: catastrophic care 'insurance' coupled with HSA (shop around for competitively priced, best value goods and services...with 'your own money').
    Will Regime be made to follow its own rules under single payer system? Or will insiders have access to a velvet-roped VIP treatment area?

    • @robert1200
      @robert1200 3 หลายเดือนก่อน

      The statistics for weight loss without a GLP-1 or bariatric surgery are pretty dismal. Most people will lose the weight if they try hard enough, but then gain it right back

    • @NANA-nd1kq
      @NANA-nd1kq 3 หลายเดือนก่อน

      @@robert1200 Don't they need to (continue to) eat less in either case?
      Why not offer a choice of cash in hand (in an amount which would also 'benefit the commons')?
      Are you suggesting people are so willfully ignorant and selfish that they would insist on 'the commons' risking extinction rather than take a somewhat significant personal reward offered for good behavior?